Immunotherapy for Advanced Non-small Cell Lung Cancer: Research Progress and Perspectives
10.3971/j.issn.1000-8578.2024.24.0090
- VernacularTitle:晚期非小细胞肺癌免疫治疗：研究进展和展望
- Author:
Jingyi WANG
1
;
Yuling ZHONG
2
;
Lin WU
1
Author Information
1. The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
2. Graduate Collaborative Training Base of Hunan Cancer Hospital, University of South China, Hengyang Medical School, Hengyang 421001, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Non-small cell lung cancer;
Immunotherapy;
Immune checkpoint inhibitors
- From:
Cancer Research on Prevention and Treatment
2024;51(6):409-418
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy has changed the treatment landscape of advanced non-small cell lung cancer (NSCLC), showing great potential in the treatment of untreated and relapsed or refractory (R/R) patients. However, numerous issues that need further exploration remain with the wide application of immunotherapy. They include the exploration of biomarkers for efficacy prediction, the optimization of immunotherapy modalities, immune-related adverse effects, and the management of special populations. This review summarizes the progress of the research on immunotherapy for advanced NSCLC and discusses its challenges and future directions.
